Clinical Trial Update: Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of fruquintinib, camrelizumab, and capecitabine as salvage therapy for unresectable/metastatic colorectal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Capecitabine (capecitabine)
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Unresectable/Metastatic Colorectal Cancer | Phase 2 | Status: RECRUITING